Cognitive impairment associated with schizophrenia (CIAS) is an important treatment target, and major unmet therapeutic need in the chronic stages of schizophrenia. Many studies have sought to ameliorate CIAS with new drugs but, as yet, no drug has been approved for treatment of CIAS. In acute stages of the illness the measurement of cognition has also been used to guide decisions about the safety and efficacy of new medicines. In this acute stage of the illness cognitive tests have been used successfully to show the benefits of new antipsychotic medicines.
In this webinar, the presenter considers issues associated with the application of cognitive tests to guide decision making about the safety and efficacy of drugs in both the chronic and acute stages of schizophrenia.
- Paul Maruff, Chief Science Officer, Cogstate